Document is current
Any future updates will be listed below
-
Authors
Li, Shuang
Lu, Alexander J. https://orcid.org/0000-0003-2868-753X
Nagueh, Eric S.
Li, Yanqiang https://orcid.org/0000-0001-6846-6884
Graber, Michael https://orcid.org/0000-0003-2150-5473
Carter, Kaylee N. https://orcid.org/0009-0002-8920-3033
Morales, Elisa
Kriss, Crystina L.
Chen, Kaifu https://orcid.org/0000-0003-1009-4357
Liu, Junchen
Wang, Guangyu
Cooke, John P.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL169204-01A1, F30 HL167547, HL169204-01A1, HL148338, HL148338, HL169204-01A1, HL148338, HL148338, HL133254, HL1577990, HL148338)
American Heart Association (25POST1378365)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM151280, 1R35GM150460)
Cancer Prevention and Research Institute of Texas (RP250213, RP150611)
- License Information
-
More Information
Article History
Received: 14 May 2024
Accepted: 13 May 2025
First Online: 4 July 2025
Competing interests
: L.L. and J.P.C. are inventors on a patent assigned to Houston Methodist Hospital on the use of modulators of O-GlcNAcylation for the treatment of vascular diseases (inventors J.P.C. (Houston, TX), L.L. (Houston, TX)/Houston Methodist Hospital (Houston, TX); publication number 20250114337; status, application pending; specific aspect of this study covered in the patent application: the invention is a therapeutic approach for modulating cellular transdifferentiation and potentially angiogenesis by modulating O-GlcNAcylation (GlcNAc) of proteins to treat various conditions. The inventors used existing small molecules to prove the concept in vitro and in vivo. The projected use includes (1) wound or fracture healing and treating vascularization (ischemic tissues, coronary, cerebral and peripheral arterial disease) by enhancing the O-GlcNAcylation pathway, potentially enhancing angiogenesis and (2) treating tumor neovascularization or excess vascularization (age-related macular degeneration, diabetic retinopathy, telangiectasias, AV malformations) by inhibiting the GlcNAcylation pathway, potentially inhibiting angiogenesis). The remaining authors declare no competing interests.
